Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025
Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...
pharmaphorum3d
CHMP backs Lilly’s Baqsimi as non-injectable for severe low blood sugar
The EMA’s human medicines advisory committee has recommended approval of Eli Lilly’s Baqsimi as the first needle-free treatment for severe low blood sugar levels (hypoglycaemia) in diabetics ...